BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Noguchi Y, Saito A, Miyagi Y, Yamanaka S, Marat D, Doi C, Yoshikawa T, Tsuburaya A, Ito T, Satoh S. Suppression of facilitative glucose transporter 1 mRNA can suppress tumor growth. Cancer Lett. 2000;154:175-182. [PMID: 10806305 DOI: 10.1016/s0304-3835(00)00392-x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
Number Citing Articles
1 Hong R, Lim SC. 18F-fluoro-2-deoxyglucose uptake on PET CT and glucose transporter 1 expression in colorectal adenocarcinoma. World J Gastroenterol 2012; 18(2): 168-174 [PMID: 22253523 DOI: 10.3748/wjg.v18.i2.168] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
2 Yan SX, Luo XM, Zhou SH, Bao YY, Fan J, Lu ZJ, Liao XB, Huang YP, Wu TT, Wang QY. Effect of antisense oligodeoxynucleotides glucose transporter-1 on enhancement of radiosensitivity of laryngeal carcinoma. Int J Med Sci 2013;10:1375-86. [PMID: 23983599 DOI: 10.7150/ijms.6855] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
3 Chung FY, Huang MY, Yeh CS, Chang HJ, Cheng TL, Yen LC, Wang JY, Lin SR. GLUT1 gene is a potential hypoxic marker in colorectal cancer patients. BMC Cancer 2009;9:241. [PMID: 19619276 DOI: 10.1186/1471-2407-9-241] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 3.9] [Reference Citation Analysis]
4 Pragallapati S, Manyam R. Glucose transporter 1 in health and disease. J Oral Maxillofac Pathol 2019;23:443-9. [PMID: 31942129 DOI: 10.4103/jomfp.JOMFP_22_18] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
5 Baczewska M, Bojczuk K, Kołakowski A, Dobroch J, Guzik P, Knapp P. Obesity and Energy Substrate Transporters in Ovarian Cancer-Review. Molecules 2021;26:1659. [PMID: 33809784 DOI: 10.3390/molecules26061659] [Reference Citation Analysis]
6 Rathmell JC, Fox CJ, Plas DR, Hammerman PS, Cinalli RM, Thompson CB. Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factor-independent survival. Mol Cell Biol 2003;23:7315-28. [PMID: 14517300 DOI: 10.1128/MCB.23.20.7315-7328.2003] [Cited by in Crossref: 408] [Cited by in F6Publishing: 224] [Article Influence: 22.7] [Reference Citation Analysis]
7 Yu M, Yongzhi H, Chen S, Luo X, Lin Y, Zhou Y, Jin H, Hou B, Deng Y, Tu L, Jian Z. The prognostic value of GLUT1 in cancers: a systematic review and meta-analysis. Oncotarget 2017;8:43356-67. [PMID: 28498810 DOI: 10.18632/oncotarget.17445] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 18.7] [Reference Citation Analysis]
8 Xu CT, Huang LT, Pan BR. Current gene therapy for stomach carcinoma. World J Gastroenterol 2001; 7(6): 752-759 [PMID: 11819868 DOI: 10.3748/wjg.v7.i6.752] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
9 Yan S, Wang Y, Chen M, Li G, Fan J. Deregulated SLC2A1 Promotes Tumor Cell Proliferation and Metastasis in Gastric Cancer. Int J Mol Sci 2015;16:16144-57. [PMID: 26193257 DOI: 10.3390/ijms160716144] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
10 Young CD, Lewis AS, Rudolph MC, Ruehle MD, Jackman MR, Yun UJ, Ilkun O, Pereira R, Abel ED, Anderson SM. Modulation of glucose transporter 1 (GLUT1) expression levels alters mouse mammary tumor cell growth in vitro and in vivo. PLoS One. 2011;6:e23205. [PMID: 21826239 DOI: 10.1371/journal.pone.0023205] [Cited by in Crossref: 122] [Cited by in F6Publishing: 116] [Article Influence: 12.2] [Reference Citation Analysis]
11 Lecca P, Morpurgo D. Modelling non-homogeneous stochastic reaction-diffusion systems: the case study of gemcitabine-treated non-small cell lung cancer growth. BMC Bioinformatics 2012;13 Suppl 14:S14. [PMID: 23095709 DOI: 10.1186/1471-2105-13-S14-S14] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
12 Pereira PM, Silva S, Cavaleiro JA, Ribeiro CA, Tomé JP, Fernandes R. Galactodendritic phthalocyanine targets carbohydrate-binding proteins enhancing photodynamic therapy. PLoS One 2014;9:e95529. [PMID: 24763311 DOI: 10.1371/journal.pone.0095529] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 5.6] [Reference Citation Analysis]
13 Fujita M, Yasuda M, Kitatani K, Miyazawa M, Hirabayashi K, Takekoshi S, Iida T, Hirasawa T, Murakami M, Mikami M. An up-to-date anti-cancer treatment strategy focusing on HIF-1alpha suppression: its application for refractory ovarian cancer. Acta Histochem Cytochem. 2007;40:139-142. [PMID: 18224245 DOI: 10.1267/ahc.07024] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
14 Sharma B, Singh S, Kanwar SS. L-methionase: a therapeutic enzyme to treat malignancies. Biomed Res Int 2014;2014:506287. [PMID: 25250324 DOI: 10.1155/2014/506287] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
15 Sadlecki P, Bodnar M, Grabiec M, Marszalek A, Walentowicz P, Sokup A, Zegarska J, Walentowicz-Sadlecka M. The role of Hypoxia-inducible factor-1 α , glucose transporter-1, (GLUT-1) and carbon anhydrase IX in endometrial cancer patients. Biomed Res Int 2014;2014:616850. [PMID: 24745019 DOI: 10.1155/2014/616850] [Cited by in Crossref: 26] [Cited by in F6Publishing: 32] [Article Influence: 3.7] [Reference Citation Analysis]
16 Tilekar K, Upadhyay N, Hess JD, Macias LH, Mrowka P, Aguilera RJ, Meyer-Almes FJ, Iancu CV, Choe JY, Ramaa CS. Structure guided design and synthesis of furyl thiazolidinedione derivatives as inhibitors of GLUT 1 and GLUT 4, and evaluation of their anti-leukemic potential. Eur J Med Chem 2020;202:112603. [PMID: 32634629 DOI: 10.1016/j.ejmech.2020.112603] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]